Zealand Pharma A/S
ZEAL
주식 순위
#5483
Zealand Pharma A/S is a Danish biotechnology firm dedicated to the... Zealand Pharma A/S is a Danish biotechnology firm dedicated to the identification, progression, and market introduction of peptide-based therapeutics. The company concentrates its efforts on treatments for gastrointestinal and metabolic ailments, as well as other specialized conditions where current medical options are insufficient. Its commercialized product, Dasiglucagon, is an injectable solution provided in a pre-filled syringe or autoinjector, used to address severe hypoglycemia. Furthermore, Zealand Pharma is actively developing Dasiglucagon for inclusion in bi-hormone artificial pancreas systems that integrate both insulin and dasiglucagon. The compound Dasiglucagon is also undergoing late-stage (Phase III) clinical trials for congenital hyperinsulinism. Another significant asset in its development pipeline is glepaglutide, a long-acting GLP-2 analog, which is likewise in Phase III clinical studies for treating short bowel syndrome. Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma A/S maintains strategic alliances with a range of partners, including Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc.
주가
$35.84
마지막 동기화: 2026-10-16
시가총액
$2.49B
변동 (1일)
-1.27%
변동 (1년)
-49.95%
국가
DK
거래 Zealand Pharma A/S (ZEAL)
카테고리
Healthcare
의 시가총액 Zealand Pharma A/S(ZEAL)
시가총액: $2.49B
October 2026 기준으로 Zealand Pharma A/S의 시가총액은 $2.49B입니다. 이는 당사 데이터에 따르면 Zealand Pharma A/S이 세계에서 5483rd번째로 가치 있는 기업임을 의미합니다. 시가총액은 상장된 회사의 발행 주식 총 시장 가치를 의미하며, 일반적으로 회사의 가치를 측정하는 데 사용됩니다.
2013부터 2026까지 Zealand Pharma A/S의 시가총액 기록
